Island Pharmaceuticals Limited (ILA)

Overview

Island Pharmaceuticals Limited is a dedicated drug research and repurposing company, with a primary focus on developing preventative or therapeutic drugs aimed at targeting viral infections. Based in Camberwell, Australia, this innovative company was incorporated in 2020 and has since engaged in significant collaborations with prestigious institutions such as Monash University, Griffith University, and Compounds Australia. Additionally, it has forged a cooperative research and development agreement with the U.S. Army, particularly in preparation for the Phase II clinical study of its lead product candidate, ISLA-101. Island Pharmaceuticals is poised at the forefront of biotechnology, leveraging existing molecular knowledge and innovative partnerships to advance the fight against major public health threats, particularly those caused by mosquito-borne diseases.

Products and Services

• ISLA-101
  

  The flagship product of Island Pharmaceuticals, ISLA-101, is undergoing development as a drug aimed at the prevention and treatment of dengue fever, along with other mosquito-borne diseases. The company's focus on this product showcases its commitment to combating some of the most challenging and prevalent viral infections affecting tropical and subtropical regions worldwide. In collaboration with the U.S. Army, the company is preparing ISLA-101 for a Phase II clinical study. Furthermore, the company has secured a supply agreement with Catalent for the manufacture of Fenretinide softgels, which are to be used in trials involving dengue fever participants. An added advantage for Island Pharmaceuticals is the right to reference the National Cancer Institute IND (Investigational New Drug application) for Isla101, potentially expediting its development and regulatory approval process.

• Collaborations for Drug Research and Repurposing
  

  Island Pharmaceuticals has established several research collaboration agreements to bolster its product development efforts. A key partnership with Monash University allows the company to screen known molecules against host targets, which is pivotal for identifying potential therapeutics for viral infections. Additionally, a research and development collaboration with Griffith University focuses on screening for active anti-viral molecules through a rational repurposing strategy, potentially speeding up the discovery and development process of new drugs. The company’s collaboration with Compounds Australia provides access to a vast drug library containing various molecules, facilitating the search for drug re-purposing opportunities and pipeline development. These collaborations exemplify Island Pharmaceuticals' strategic approach to leverage partnerships in expediting its research and development endeavors.